Eusa Pharma appoints Iain McGill
pharmafile | March 10, 2010 | Appointment | Sales and Marketing | Eusa Pharma, appointment, sales and marketing
Iain McGill has joined specialty company Eusa Pharma as international and European president.
He moves to Eusa from Wyeth Pharmaceutical, where he was vice president and global manager for its transplantation business.
Prior to this he was head of Novartis’ Transplantation, Immunology and Infectious Diseases business unit in Canada, and before that a global brand director at Novartis’ headquarters in Switzerland.
He has also held a number of sales and marketing positions of increasing seniority at Novartis and Roche in the UK.
The company said McGill’s appointment finalised its executive management team and commercial infrastructure.
“We are delighted to welcome Iain to EUSA at such an exciting time in the company’s development,” said Bryan Morton, Eusa Pharma’s president and chief executive.
“Since founding Eusa four years ago, we have made tremendous progress, raising over $300 million in investment funding, establishing a portfolio of eight marketed and four pipeline products, and building a strong commercialisation platform on both sides of the Atlantic.”
Eusa now has a presence in over 80 countries, with teams covering the US and over 20 European territories including the major EU markets, and the company anticipates strong sales growth and profitability in 2010.
Related Content
EUSA Pharma gets FDA green light to evaluate IL-6 inhibitor siltuximab in COVID-19 patients
Efforts push on to discover an effective treatment for COVID-19 in more than 100 different …
EUSA Pharma’s COVID-19 drug improves or stabilises respiratory condition in 76% of patients
EUSA Pharma has unveiled promising preliminary findings from an interim analysis of siltuximab in the …
EUSA Pharma and Ergomed partner to investigate IL-6 targeting in COVID-19 patients with serious respiratory complications
Oncology and rare disease firm EUSA Pharma is aiding in the global fight against the …